menu
    • menu
    [{"orgOrder":0,"company":"Ligachem Biosciences","sponsor":"NextCure","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"LNCB74","moa":"B7-H4","graph1":"Oncology","graph2":"Phase I","graph3":"Ligachem Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ligachem Biosciences \/ Ligachem Biosciences","highestDevelopmentStatusID":"6","companyTruncated":"Ligachem Biosciences \/ Ligachem Biosciences"},{"orgOrder":0,"company":"Ligachem Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Delpazolid","moa":"Bacterial 70S ribosome","graph1":"Undisclosed","graph2":"Phase I","graph3":"Ligachem Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ligachem Biosciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Ligachem Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Ligachem Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Delpazolid","moa":"Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Ligachem Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ligachem Biosciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Ligachem Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Ligachem Biosciences","sponsor":"Ludwig Maximilian University of Munich | Radboud University Medical Center | University of California, San Francisco","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Delpazolid","moa":"Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Ligachem Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ligachem Biosciences \/ Ludwig Maximilian University of Munich | Radboud University Medical Center | University of California, San Francisco","highestDevelopmentStatusID":"8","companyTruncated":"Ligachem Biosciences \/ Ludwig Maximilian University of Munich | Radboud University Medical Center | University of California, San Francisco"},{"orgOrder":0,"company":"Ligachem Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Delpazolid","moa":"Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Ligachem Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ligachem Biosciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Ligachem Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Ligachem Biosciences","sponsor":"Ono Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Antibody-drug Conjugate","year":"2024","type":"Licensing Agreement","leadProduct":"LCB97","moa":"L1CAM\/Tubulin","graph1":"Oncology","graph2":"Preclinical","graph3":"Ligachem Biosciences","amount2":0.69999999999999996,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0.69999999999999996,"dosageForm":"Undisclosed","sponsorNew":"Ligachem Biosciences \/ Ono Pharmaceutical","highestDevelopmentStatusID":"4","companyTruncated":"Ligachem Biosciences \/ Ono Pharmaceutical"},{"orgOrder":0,"company":"Ligachem Biosciences","sponsor":"AntibodyChem Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"LCB84","moa":"Trop2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ligachem Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ligachem Biosciences \/ AntibodyChem Biosciences","highestDevelopmentStatusID":"7","companyTruncated":"Ligachem Biosciences \/ AntibodyChem Biosciences"},{"orgOrder":0,"company":"Ligachem Biosciences","sponsor":"WuXi XDC","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Ligachem Biosciences","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ligachem Biosciences \/ Ligachem Biosciences","highestDevelopmentStatusID":"3","companyTruncated":"Ligachem Biosciences \/ Ligachem Biosciences"},{"orgOrder":0,"company":"Ligachem Biosciences","sponsor":"Samsung Biologics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2025","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Ligachem Biosciences","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ligachem Biosciences \/ Ligachem Biosciences","highestDevelopmentStatusID":"1","companyTruncated":"Ligachem Biosciences \/ Ligachem Biosciences"},{"orgOrder":0,"company":"Ligachem Biosciences","sponsor":"DAAN Biotherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2025","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Ligachem Biosciences","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ligachem Biosciences \/ Ligachem Biosciences","highestDevelopmentStatusID":"3","companyTruncated":"Ligachem Biosciences \/ Ligachem Biosciences"}]

    Find Clinical Drug Pipeline Developments & Deals by Ligachem Biosciences

    Menu

    Ligachem Biosciences

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Ligachem Biosciences

                            South Korea arrow
                            FNCE
                            Not Confirmed

                            Ligachem Biosciences

                            South Korea arrow
                            FNCE
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Discovery Platform

                            Recipient : WuXi XDC

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            WuXi XDC & LigaChem Expand MOU to Boost ADC Development

                            Details : Through the collaboration, WuXi XDC's fully integrated ADC discovery service platform will significantly boost the speed and efficiency of LigaChem's ADC development programs.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            February 25, 2025

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery Platform

                            Recipient : WuXi XDC

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Ligachem Biosciences

                            South Korea arrow
                            FNCE
                            Not Confirmed

                            Ligachem Biosciences

                            South Korea arrow
                            FNCE
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Discovery Platform

                            Recipient : DAAN Biotherapeutics

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            DAAN Biotherapeutics, LigaChem Partner on ADC Antibody Licensing Deal

                            Details : Under the licensing agreement, LigaChem will leverage DAAN Biotherapeutics' next-generation antibody technology for the treatment of solid tumor patients.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            February 13, 2025

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery Platform

                            Recipient : DAAN Biotherapeutics

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Ligachem Biosciences

                            South Korea arrow
                            FNCE
                            Not Confirmed

                            Ligachem Biosciences

                            South Korea arrow
                            FNCE
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : LNCB74

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Recipient : NextCure

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Phase 1 Study of LNCB74 in Advanced Solid Tumors

                            Details : LNCB74 is a Antibody-drug Conjugate drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Ovarian Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Antibody-drug Conjugate

                            Upfront Cash : Inapplicable

                            January 14, 2025

                            Lead Product(s) : LNCB74

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Recipient : NextCure

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Ligachem Biosciences

                            South Korea arrow
                            FNCE
                            Not Confirmed

                            Ligachem Biosciences

                            South Korea arrow
                            FNCE
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Undisclosed

                            Recipient : Samsung Biologics

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Samsung Biologics Extends Collaboration with LigaChem Biosciences for ADC Development

                            Details : The collaboration will further strengthen LigaChem Biosciences capabilities across all stages of ADC development to treat solid tumors.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            January 08, 2025

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Undisclosed

                            Recipient : Samsung Biologics

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Ligachem Biosciences

                            South Korea arrow
                            FNCE
                            Not Confirmed

                            Ligachem Biosciences

                            South Korea arrow
                            FNCE
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : LCB97

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Ono Pharmaceutical

                            Deal Size : $700.0 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Ono Inks $700M Biobuck Deal to Bag Preclinical LigaChem ADC

                            Details : Ono will have an exclusive worldwide right to develop, manufacture and commercialize LCB97, a pre-clinical stage antibody-drug conjugate, for solid tumors.

                            Product Name : Undisclosed

                            Product Type : Antibody-drug Conjugate

                            Upfront Cash : Undisclosed

                            October 10, 2024

                            Lead Product(s) : LCB97

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Ono Pharmaceutical

                            Deal Size : $700.0 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Ligachem Biosciences

                            South Korea arrow
                            FNCE
                            Not Confirmed

                            Ligachem Biosciences

                            South Korea arrow
                            FNCE
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Delpazolid

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study to Evaluate the Efficacy of Delpazolid As Add-on Therapy in Refractory Mycobacterium Abscessus Complex

                            Details : Delpazolid is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Mycobacterium Infections, Nontuberculous.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            August 22, 2023

                            Lead Product(s) : Delpazolid

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Ligachem Biosciences

                            South Korea arrow
                            FNCE
                            Not Confirmed

                            Ligachem Biosciences

                            South Korea arrow
                            FNCE
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : LCB84

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : AntibodyChem Biosciences

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tum...

                            Details : LCB84 is a Other Large Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            July 12, 2023

                            Lead Product(s) : LCB84

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : AntibodyChem Biosciences

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Ligachem Biosciences

                            South Korea arrow
                            FNCE
                            Not Confirmed

                            Ligachem Biosciences

                            South Korea arrow
                            FNCE
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Delpazolid

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Phase 2a Study, Effect of Vancomycin With vs Without Delpazolid (LCB01-0371) in Patients With MRSA Bacteremi...

                            Details : Delpazolid is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Staphylococcal Infections.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            February 04, 2022

                            Lead Product(s) : Delpazolid

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Ligachem Biosciences

                            South Korea arrow
                            FNCE
                            Not Confirmed

                            Ligachem Biosciences

                            South Korea arrow
                            FNCE
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Delpazolid

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Trial to Evaluate Bioequivalence of LCB01-0371 in Different Batches

                            Details : LCB01-0371 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            June 25, 2021

                            Lead Product(s) : Delpazolid

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Ligachem Biosciences

                            South Korea arrow
                            FNCE
                            Not Confirmed

                            Ligachem Biosciences

                            South Korea arrow
                            FNCE
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Delpazolid

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : Ludwig Maximilian University of Munich | Radboud University Medical Center | University of California, San Francisco

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            PanACEA DElpazolid Dose-finding and COmbination DEvelopment (DECODE)

                            Details : Delpazolid is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Infections.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            September 16, 2020

                            Lead Product(s) : Delpazolid

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : Ludwig Maximilian University of Munich | Radboud University Medical Center | University of California, San Francisco

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth